Gain Therapeutics (GANX) Q3 2026 earnings summary

Executive summary

• Rexaceract is being developed for Parkinson’s disease with and without GBA1 mutations; Phase 2a is targeted to start in Q1 2027 after FDA IND authorization in June 2026.

• Twelve-month open-label data showed stable MDS-UPDRS Parts II and III scores, generally good tolerability and no new safety signals.

• Q3 losses narrowed as expenses declined, but $11.7M cash is expected to fund needs only into Q2 2027; additional financing is required.

Financial highlights

• Q3 operating expenses were $3.20M versus $4.79M; R&D was $1.42M versus $2.85M, and G&A was $1.78M versus $1.94M.

• Q3 net loss was $3.16M, or $0.07/share, versus $5.28M, or $0.15/share; nine-month net loss was $13.44M, or $0.31/share, versus $15.62M, or $0.50/share.

• Nine-month R&D was $6.32M versus $7.87M; G&A was $6.91M versus $6.38M.

• Cash and cash equivalents were $11.7M at September 30, 2026, versus $20.8M at December 31, 2025; accumulated deficit was $114.8M.

• Nine-month operating cash use was $12.5M versus $13.8M; financing provided $3.5M versus $12.0M.

Outlook and guidance

• Phase 1b Part 2 is expected to complete in Q4 2026; the Phase 2a protocol submission and design updates are expected in Q4 2026, with trial initiation targeted for Q1 2027.

• Phase 2a is planned across U.S., Australian and European sites; timing depends on protocol redesign, regulatory submission and enrollment.

• Cash is expected to fund anticipated operating and capital needs into Q2 2027, but not 12 months from financial-statement issuance; additional capital is required beyond Q2 2027.

• R&D spending is expected to rise with clinical development; cost reviews and equity or debt financing, collaborations, licensing and grants are being pursued.

• GT-04686’s initial target indication is expected in Q4 2026; a second allosteric small-molecule candidate is planned for clinical development.